The journey of Sotagliflozin: from its status as a withdrawn candidate for the treatment of diabetes mellitus, to its repurposing as a groundbreaking drug for the management of heart failure. Pharm Pract (Granada) [Internet]. 2025 Oct. 8 [cited 2025 Oct. 22];23(3):1-10. Available from: https://pharmacypractice.org/index.php/pp/article/view/3265